MCID: BLM002
MIFTS: 52

Bulimia Nervosa malady

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Bulimia Nervosa

Aliases & Descriptions for Bulimia Nervosa:

Name: Bulimia Nervosa 12 52 14 69
Bulimia 42 69
Bulimia Nervosa, Susceptibility to 13
Binge Eating Disorder 69
Hyperorexia Nervosa 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12129
ICD10 33 F50.2
MeSH 42 D002032
NCIt 47 C97162
UMLS 69 C0006370

Summaries for Bulimia Nervosa

Disease Ontology : 12 An eating disorder characterized by the restraining of food intake for a period of time followed by an over intake or binging period that results in feelings of guilt and low self-esteem.

MalaCards based summary : Bulimia Nervosa, also known as bulimia, is related to personality disorder and body dysmorphic disorder, and has symptoms including salt craving and symptoms. An important gene associated with Bulimia Nervosa is GHRL (Ghrelin And Obestatin Prepropeptide), and among its related pathways/superpathways are Peptide ligand-binding receptors and cAMP signaling pathway. The drugs Cisplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include skin, brain and testes, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Wikipedia : 71 Bulimia nervosa, also known as simply bulimia, is an eating disorder characterized by binge eating... more...

Related Diseases for Bulimia Nervosa

Diseases related to Bulimia Nervosa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 101)
id Related Disease Score Top Affiliating Genes
1 personality disorder 30.1 BDNF CCK COMT HTR2A SLC6A4
2 body dysmorphic disorder 29.4 GHRL LEP MC4R NPY
3 anorexia nervosa 12.2
4 bulimia nervosa, age of onset of weight loss in 12.1
5 eating disorder 11.7
6 anorexia nervosa 1 11.1
7 obesity 10.3
8 borderline personality disorder 10.3
9 dyspepsia 10.2 CCK NPY
10 tricuspid valve stenosis 10.2 CCK PYY
11 cerebritis 10.2
12 teratoma with malignant transformation 10.1 BDNF HTR2A
13 gastric dilatation 10.1
14 roifman-chitayat syndrome 10.1 GHRL LEP PYY
15 dry eye syndrome 10.1 HTR2A SLC6A4
16 hyperornithinemia-hyperammonemia-homocitrullinemia syndrome 10.1 CCK GHRL PYY
17 splenic abscess 10.1 HTR2A SLC6A4
18 childhood malignant hemangiopericytoma 10.1 CCK GHRL PYY
19 diabetic encephalopathy 10.1 GHRL HTR2A LEP
20 obesity, ucp3-related 10.1 GHRL MC4R
21 euthyroid sick syndrome 10.1 HTR2A SLC6A4
22 hypoglycemic coma 10.1 BDNF HTR2A SLC6A4
23 cardioauditory syndrome of sanchez cascos 10.1 HTR3A NPY PYY
24 scleral staphyloma 10.1 CCK GHRL HTR3A
25 neurogenic bladder 10.0 HTR2A SLC6A4
26 ischemic neuropathy 10.0 CCK GHRL HTR3A
27 chronic eosinophilic pneumonia 10.0 BDNF COMT SLC6A4
28 waardenburg's syndrome 10.0 HTR2A SLC6A4
29 ornithosis 10.0 CCK HTR3A SLC6A4
30 deafness, autosomal recessive 20 10.0 CCK HTR3A SLC6A4
31 apperceptive agnosia 10.0 COMT SLC6A4
32 tuberculous peritonitis 10.0 CCK HTR3A SLC6A4
33 pyromania 10.0 HTR2A SLC6A4
34 nephronophthisis 13 10.0 COMT HTR2A SLC6A4
35 epithelioid type angiomyolipoma 10.0 BDNF HTR2A SLC6A4
36 hypereosinophilic syndrome 10.0 BDNF HTR1B SLC6A4
37 lichen disease 9.9 COMT HTR2A SLC6A4
38 rectal prolapse 9.9
39 attention deficit-hyperactivity disorder 9.9
40 esophagitis 9.9
41 substance dependence 9.9
42 pathological gambling 9.9
43 avoidant personality disorder 9.9
44 obsessive-compulsive disorder 9.9
45 hypokalemia 9.9
46 compartment syndrome 9.9
47 mandibular cancer 9.9 CCK GHRL HTR3A SLC6A4
48 sweat gland cancer 9.9 CCK HTR3A PYY SLC6A4
49 intrahepatic gall duct cancer 9.9 BDNF COMT HTR2A SLC6A4
50 primary angle-closure glaucoma 9.9 BDNF COMT HTR2A SLC6A4

Graphical network of the top 20 diseases related to Bulimia Nervosa:



Diseases related to Bulimia Nervosa

Symptoms & Phenotypes for Bulimia Nervosa

UMLS symptoms related to Bulimia Nervosa:


salt craving, symptoms

MGI Mouse Phenotypes related to Bulimia Nervosa:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.15 BDNF CCK COMT GHRL HTR1B HTR2A
2 endocrine/exocrine gland MP:0005379 9.97 BDNF CCK COMT GHRL HTR1B HTR2A
3 growth/size/body region MP:0005378 9.86 SLC6A4 BDNF HTR1B HTR3A LEP MC4R
4 homeostasis/metabolism MP:0005376 9.85 COMT GHRL HTR3A LEP MC4R NPY
5 adipose tissue MP:0005375 9.8 GHRL LEP MC4R NPY PYY
6 nervous system MP:0003631 9.61 BDNF CCK COMT HTR3A LEP MC4R
7 normal MP:0002873 9.1 BDNF GHRL MC4R NPY PYY SLC6A4

Drugs & Therapeutics for Bulimia Nervosa

Drugs for Bulimia Nervosa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 368)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2 15663-27-1 84093 441203 2767
2
Gemcitabine Approved Phase 4 95058-81-4 60750
3
Cytarabine Approved, Investigational Phase 4 147-94-4 6253
4
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1 97240-79-4 5284627
5
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
6
Memantine Approved, Investigational Phase 4 19982-08-2 4054
7
Norepinephrine Approved Phase 4 51-41-2 439260
8
Liraglutide Approved Phase 4,Phase 3 204656-20-2
9
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
10
Budesonide Approved Phase 4 51333-22-3 63006 5281004
11
Ipratropium Approved Phase 4 22254-24-6, 60205-81-4 43232
12
Theophylline Approved Phase 4 58-55-9 2153
13
Amphetamine Approved, Illicit Phase 4 300-62-9 5826 3007
14
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
15
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
16
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
17
Fludarabine Approved Phase 4 21679-14-1, 75607-67-9 30751
18
Vidarabine Approved Phase 4 24356-66-9 32326 21704
19
Ticlopidine Approved Phase 4 55142-85-3 5472
20
Insulin Glargine Approved Phase 4 160337-95-1
21
Acetaminophen Approved Phase 4 103-90-2 1983
22
Guaifenesin Approved, Vet_approved Phase 4 93-14-1 3516
23
Hydrocodone Approved, Illicit Phase 4 125-29-1 5284569
24
Ibuprofen Approved Phase 4 15687-27-1 3672
25
Exemestane Approved, Investigational Phase 4,Phase 2 107868-30-4 60198
26
Goserelin Approved Phase 4,Phase 2 65807-02-5 47725 5311128
27
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
28
Tamoxifen Approved Phase 4,Phase 2 10540-29-1 2733526
29
Clopidogrel Approved, Nutraceutical Phase 4 120202-66-6, 113665-84-2 60606
30 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Antimetabolites Phase 4,Phase 3,Phase 1,Phase 2
32 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 1,Phase 2
33 Antiviral Agents Phase 4,Phase 2,Phase 3
34 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
35 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Adrenergic Agents Phase 4,Phase 2,Phase 1
37 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
38 Anti-Obesity Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Hormone Antagonists Phase 4,Phase 3,Phase 2
40 Hormones Phase 4,Phase 3,Phase 2
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
42 Adrenergic Agonists Phase 4
43 Adrenergic beta-2 Receptor Agonists Phase 4
44 Adrenergic beta-Agonists Phase 4
45 Anti-Asthmatic Agents Phase 4
46 Anti-Inflammatory Agents Phase 4,Phase 3
47 Autonomic Agents Phase 4,Phase 2,Phase 1
48 Bronchodilator Agents Phase 4
49 Respiratory System Agents Phase 4,Phase 2,Phase 3
50 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 415)
id Name Status NCT ID Phase
1 Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
2 Maintenance Gemcitabine in the Chinese Advanced Lung Cancer Unknown status NCT01336192 Phase 4
3 A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure Unknown status NCT02135835 Phase 4
4 Treatment of Cranial Internal Carotid Artery Aneurysm With Willis Covered Stent and Coil Embolization Unknown status NCT01029938 Phase 4
5 An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder Completed NCT00330655 Phase 4
6 Atomoxetine in the Treatment of Binge Eating Disorder Completed NCT00327834 Phase 4
7 Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression Completed NCT00607789 Phase 4
8 Treatment of Binge Eating in Obese Patients in Primary Care Completed NCT00537810 Phase 4
9 Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese Completed NCT01739049 Phase 4
10 Effectiveness of Binge Eating Disorder Treatments Completed NCT00060762 Phase 4
11 Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons Completed NCT00516919 Phase 4
12 Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults Completed NCT02706067 Phase 4
13 Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients Completed NCT01415518 Phase 4
14 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4
15 Antidepressant Safety in Kids Study Completed NCT00395213 Phase 4
16 Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML Recruiting NCT02926586 Phase 4
17 Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding Recruiting NCT01806090 Phase 4
18 Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment Recruiting NCT02535299 Phase 4
19 Narcotic vs. Non-narcotic Pain Study Protocol Recruiting NCT01974609 Phase 4
20 Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF. Recruiting NCT02359513 Phase 4
21 Effect of Intensive Therapy Associated With CSII on β-cell Function With Newly Diagnosed Type 2 Diabetes Enrolling by invitation NCT00948324 Phase 4
22 A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations (STEP) Not yet recruiting NCT03137368 Phase 4
23 Topiramate Augmentation in Bulimia Nervosa Partial Responders Withdrawn NCT00988481 Phase 4
24 Clinical Trial on Binge Eating Disorder, Treatment With Naloxone Spray Unknown status NCT01567670 Phase 2, Phase 3
25 Improving Patient Outcome in Group Therapy for Eating Disorders Unknown status NCT01693237 Phase 2, Phase 3
26 Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients With Onset of Type 1 Diabetes Unknown status NCT01157403 Phase 2, Phase 3
27 Medication and Counseling for Controlled Drinking Unknown status NCT01115894 Phase 3
28 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
29 ABMSC Infusion Through Hepatic Artery in Portal Hypertension Surgery for the Treatment of Liver Cirrhosis Unknown status NCT01560845 Phase 2, Phase 3
30 Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity Completed NCT00277641 Phase 3
31 An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder. Completed NCT00307619 Phase 3
32 Dasotraline Binge Eating Disorder Study Completed NCT02564588 Phase 2, Phase 3
33 Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder Completed NCT01090713 Phase 3
34 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718483 Phase 3
35 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718509 Phase 3
36 Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity Completed NCT00221442 Phase 3
37 A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity Completed NCT00210808 Phase 2, Phase 3
38 A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder Completed NCT00402584 Phase 3
39 Open Label Extension in Adults With Binge Eating Disorder (BED) Completed NCT01657019 Phase 3
40 Craving, Binge Eating and Obesity Completed NCT00414167 Phase 2, Phase 3
41 Meditation-Based Treatment for Binge Eating Disorder Completed NCT00032760 Phase 2, Phase 3
42 Acamprosate in the Treatment of Binge-Eating Disorder Completed NCT00511940 Phase 2, Phase 3
43 Sodium Oxybate in the Treatment of Binge Eating Disorder Completed NCT00514995 Phase 2, Phase 3
44 Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT02009163 Phase 3
45 Armodafinil in Binge Eating Disorder (BED) Completed NCT01010789 Phase 3
46 Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients Completed NCT00481975 Phase 3
47 Influence of Binge Drinking on Glucose Metabolism in Patients With Type 1 Diabetes - A Pilot Study Completed NCT00135915 Phase 2, Phase 3
48 CHIPs or College Health Intervention Projects Completed NCT00244049 Phase 3
49 Adventure: Teacher Delivered Personality-targeted Interventions for Substance Misuse Completed NCT00776685 Phase 2, Phase 3
50 Medication and Counseling for Controlled Drinking (Project SMART) Completed NCT00444418 Phase 3

Search NIH Clinical Center for Bulimia Nervosa

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: bulimia

Genetic Tests for Bulimia Nervosa

Anatomical Context for Bulimia Nervosa

MalaCards organs/tissues related to Bulimia Nervosa:

39
Skin, Brain, Testes, Cortex, Heart, Prefrontal Cortex, Pituitary

Publications for Bulimia Nervosa

Articles related to Bulimia Nervosa:

(show top 50) (show all 683)
id Title Authors Year
1
Impulsivity and test meal intake among women with bulimia nervosa. ( 28077307 )
2017
2
CBT4BN: A Randomized Controlled Trial of Online Chat and Face-to-Face Group Therapy for Bulimia Nervosa. ( 27883997 )
2017
3
Computerized assessment of body image in anorexia nervosa and bulimia nervosa: comparison with standardized body image assessment tool. ( 27796596 )
2017
4
Visual selective attention in body dysmorphic disorder, bulimia nervosa and healthy controls. ( 27998509 )
2017
5
Cue-exposure software for the treatment of bulimia nervosa and binge eating disorder. ( 27776602 )
2016
6
Personality psychopathology differentiates risky behaviors among women with bulimia nervosa. ( 27301347 )
2016
7
Social patterning of overeating, binge eating, compensatory behaviours and symptoms of bulimia nervosa in young adult women: results from the Australian Longitudinal Study on Women's Health. ( 27329947 )
2016
8
Reciprocal associations between negative affect, binge eating, and purging in the natural environment in women with bulimia nervosa. ( 26692122 )
2016
9
Impulsivity-related traits distinguish women with co-occurring bulimia nervosa in a psychiatric sample. ( 27567004 )
2016
10
Examining the role of self-discrepancy and self-directed style in bulimia nervosa. ( 27512918 )
2016
11
The ABBA study - approach bias modification in bulimia nervosa and binge eating disorder: study protocol for a randomised controlled trial. ( 27670138 )
2016
12
Reward-Based Spatial Learning in Teens With Bulimia Nervosa. ( 27806864 )
2016
13
Effects of emotional acceptance and rumination on media-induced body dissatisfaction in anorexia and bulimia nervosa. ( 27491068 )
2016
14
Mood spectrum comorbidity in patients with anorexia and bulimia nervosa. ( 27766498 )
2016
15
Stigmatizing Attitudes and Beliefs About Anorexia and Bulimia Nervosa Among Italian Undergraduates. ( 27741080 )
2016
16
Prevalence, incidence, and natural course of anorexia and bulimia nervosa among adolescents and young adults. ( 26754944 )
2016
17
Food Addiction in Bulimia Nervosa: Clinical Correlates and Association with Response to a Brief Psychoeducational Intervention. ( 27593963 )
2016
18
Altered structural and effective connectivity in anorexia and bulimia nervosa in circuits that regulate energy and reward homeostasis. ( 27801897 )
2016
19
Cardiac Risk and Disordered Eating: Decreased R Wave Amplitude in Women with Bulimia Nervosa and Women with Subclinical Binge/Purge Symptoms. ( 27511789 )
2016
20
Executive Functioning and Visuospatial Abilities in Bulimia Nervosa with or without a Previous History of Anorexia Nervosa. ( 26708940 )
2016
21
Increased temporal discounting in bulimia nervosa. ( 27301653 )
2016
22
Attention Network Dysfunction in Bulimia Nervosa - An fMRI Study. ( 27607439 )
2016
23
Hypovitaminosis D3, Leukopenia, and Human Serotonin Transporter Polymorphism in Anorexia Nervosa and Bulimia Nervosa. ( 26903713 )
2016
24
Predictors of dropout in face-to-face and internet-based cognitive-behavioral therapy for bulimia nervosa in a randomized controlled trial. ( 27862108 )
2016
25
A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder. ( 26942768 )
2016
26
Focused vs. Broad enhanced cognitive behavioral therapy for bulimia nervosa with comorbid borderline personality: A randomized controlled trial. ( 26649812 )
2016
27
Food Addiction and Bulimia Nervosa: New Data Based on the Yale Food Addiction Scale 2.0. ( 27578243 )
2016
28
How useful is the DSM-5 severity indicator in bulimia nervosa? A clinical study including a measure of impairment. ( 27788453 )
2016
29
Retrospective Correlates for Bulimia Nervosa: A Matched Case-Control Study. ( 26841218 )
2016
30
Does habituation really happen? Investigation of psycho-biological responses to body exposure in bulimia nervosa. ( 28027485 )
2016
31
Recovery From Anorexia Nervosa and Bulimia Nervosa at 22-Year Follow-Up. ( 28002660 )
2016
32
A systematic review on heart rate variability in Bulimia Nervosa. ( 26828568 )
2016
33
The relation of weight suppression and BMIz to bulimic symptoms in youth with bulimia nervosa. ( 27468352 )
2016
34
Psychoanalytic psychotherapy with a client with bulimia nervosa. ( 27267505 )
2016
35
Association of premenstrual syndrome and premenstrual dysphoric disorder with bulimia nervosa and binge-eating disorder in a nationally representative epidemiological sample. ( 27206163 )
2016
36
Predictors and moderators of treatment outcome in a randomized clinical trial for adults with symptoms of bulimia nervosa. ( 26689304 )
2016
37
Neural signature of behavioural inhibition in women with bulimia nervosa. ( 27575858 )
2016
38
Interhemispheric functional connectivity in anorexia and bulimia nervosa. ( 27992088 )
2016
39
Examining the relationship between selective attentional bias for food- and body-related stimuli and purging behaviour in bulimia nervosa. ( 27507132 )
2016
40
Elevated total plasma-adiponectin is stable over time in young women with bulimia nervosa. ( 28049078 )
2016
41
Implicit learning on a probabilistic classification task in adults and adolescents with Bulimia Nervosa. ( 26978183 )
2016
42
Smoking status and psychosocial factors in binge eating disorder and bulimia nervosa. ( 26741260 )
2016
43
Three decades of eating disorders in Dutch primary care: decreasing incidence of bulimia nervosa but not of anorexia nervosa. ( 26671456 )
2016
44
Validity and clinical utility of the DSM-5 severity specifier for bulimia nervosa: results from a multisite sample of patients who received evidence-based treatment. ( 27435722 )
2016
45
Client Attachment in a Randomized Clinical Trial of Psychoanalytic and Cognitive-Behavioral Psychotherapy for Bulimia Nervosa: Outcome Moderation and Change. ( 26950692 )
2016
46
Intensive inpatient treatment for bulimia nervosa: Statistical and clinical significance of symptom changes. ( 27456048 )
2016
47
An examination of affect prior to and following episodes of getting drunk in women with bulimia nervosa. ( 27111214 )
2016
48
Normal interoceptive accuracy in women with bulimia nervosa. ( 27138826 )
2016
49
A latent profile analysis of childhood trauma in women with bulimia nervosa: Associations with borderline personality disorder psychopathology. ( 27038436 )
2016
50
Meta-analysis of theory of mind in anorexia nervosa and bulimia nervosa: A specific A^mpairment of cognitive perspective taking in anorexia nervosa? ( 27425037 )
2016

Variations for Bulimia Nervosa

Expression for Bulimia Nervosa

Search GEO for disease gene expression data for Bulimia Nervosa.

Pathways for Bulimia Nervosa

Pathways related to Bulimia Nervosa according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.03 CCK GHRL HTR1B HTR2A LEP MC4R
2
Show member pathways
11.93 BDNF GHRL HTR1B NPY
4 11.77 BDNF HTR2A HTR3A SLC6A4
5 11.31 HTR1B HTR2A HTR3A SLC6A4
6
Show member pathways
10.84 COMT SLC6A4
7 10.73 NPY PYY
8 10.37 HTR1B HTR2A HTR3A SLC6A4

GO Terms for Bulimia Nervosa

Cellular components related to Bulimia Nervosa according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.02 CCK COMT GHRL HTR2A HTR3A

Biological processes related to Bulimia Nervosa according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.99 GHRL HTR1B HTR2A MC4R PYY
2 response to drug GO:0042493 9.8 COMT HTR1B HTR2A SLC6A4
3 chemical synaptic transmission GO:0007268 9.78 HTR1B HTR2A NPY
4 response to ethanol GO:0045471 9.72 HTR1B HTR3A LEP
5 response to cocaine GO:0042220 9.61 HTR1B HTR3A
6 insulin secretion GO:0030073 9.6 LEP MC4R
7 protein kinase C-activating G-protein coupled receptor signaling pathway GO:0007205 9.58 CCK HTR1B
8 regulation of sensory perception of pain GO:0051930 9.58 CCK COMT
9 regulation of dopamine secretion GO:0014059 9.57 HTR1B HTR2A
10 vasoconstriction GO:0042310 9.56 HTR1B SLC6A4
11 energy reserve metabolic process GO:0006112 9.54 LEP MC4R
12 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.52 HTR1B HTR2A
13 central nervous system neuron development GO:0021954 9.51 LEP NPY
14 regulation of appetite GO:0032098 9.48 NPY PYY
15 regulation of behavior GO:0050795 9.46 HTR1B HTR2A
16 negative regulation of appetite GO:0032099 9.43 CCK LEP
17 eating behavior GO:0042755 9.43 CCK LEP PYY
18 serotonin receptor signaling pathway GO:0007210 9.4 HTR2A HTR3A
19 regulation of metabolic process GO:0019222 9.37 LEP MC4R
20 behavior GO:0007610 9.33 HTR1B HTR2A NPY
21 positive regulation of appetite GO:0032100 9.32 GHRL NPY
22 adult feeding behavior GO:0008343 9.13 GHRL LEP NPY
23 feeding behavior GO:0007631 8.92 HTR1B MC4R NPY PYY

Molecular functions related to Bulimia Nervosa according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor binding GO:0001664 9.5 GHRL NPY PYY
2 neuropeptide hormone activity GO:0005184 9.43 CCK NPY PYY
3 neurotransmitter receptor activity GO:0030594 9.37 HTR1B HTR2A
4 G-protein coupled serotonin receptor activity GO:0004993 9.33 HTR1B HTR2A HTR3A
5 serotonin binding GO:0051378 9.13 HTR1B HTR2A HTR3A
6 hormone activity GO:0005179 9.02 CCK GHRL LEP NPY PYY

Sources for Bulimia Nervosa

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....